Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

single arm registrational trial in second-line advanced pleomorphic sarcoma (UPS) or dedifferentiated liposarcoma (DDLPS)

Next Previous
Trial Profile

single arm registrational trial in second-line advanced pleomorphic sarcoma (UPS) or dedifferentiated liposarcoma (DDLPS)

Status: Planning
Phase of Trial: Phase II

Latest Information Update: 04 Mar 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lifileucel (Primary)
  • Indications Liposarcoma; Malignant fibrous histiocytoma
  • Focus Registrational; Therapeutic Use

Most Recent Events

  • 04 Mar 2026 New trial record
  • 24 Feb 2026 According to an Iovance Biotherapeutics media release, the company plans to commence a single arm registrational trial in second-line advanced UPS and DDLPS in the second quarter of 2026 and will engage with the U.S. Food and Drug Administration (FDA) on an accelerated path to expedite approval.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top